Research ArticleClinical Investigation
Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology
Thomas Langbein, Hui Wang, Isabel Rauscher, Markus Kroenke, Karina Knorr, Alexander Wurzer, Kristina Schwamborn, Tobias Maurer, Thomas Horn, Bernhard Haller, Hans-Jürgen Wester and Matthias Eiber
Journal of Nuclear Medicine September 2022, 63 (9) 1334-1342; DOI: https://doi.org/10.2967/jnumed.121.263440
Thomas Langbein
1Department of Nuclear Medicine, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany;
Hui Wang
1Department of Nuclear Medicine, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany;
2Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China;
Isabel Rauscher
1Department of Nuclear Medicine, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany;
Markus Kroenke
1Department of Nuclear Medicine, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany;
Karina Knorr
1Department of Nuclear Medicine, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany;
Alexander Wurzer
3Chair of Radiopharmacy, Technical University of Munich, Munich, Germany;
Kristina Schwamborn
4Institute of Pathology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany;
Tobias Maurer
5Martini-Klinik and Department of Urology, University Hospital Hamburg–Eppendorf, Hamburg, Germany;
Thomas Horn
6Department of Urology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany; and
Bernhard Haller
7Institute of Medical Informatics, Statistics and Epidemiology, School of Medicine, Technical University of Munich, Munich, Germany
Hans-Jürgen Wester
3Chair of Radiopharmacy, Technical University of Munich, Munich, Germany;
Matthias Eiber
1Department of Nuclear Medicine, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue 9
September 1, 2022
Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology
Thomas Langbein, Hui Wang, Isabel Rauscher, Markus Kroenke, Karina Knorr, Alexander Wurzer, Kristina Schwamborn, Tobias Maurer, Thomas Horn, Bernhard Haller, Hans-Jürgen Wester, Matthias Eiber
Journal of Nuclear Medicine Sep 2022, 63 (9) 1334-1342; DOI: 10.2967/jnumed.121.263440
Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology
Thomas Langbein, Hui Wang, Isabel Rauscher, Markus Kroenke, Karina Knorr, Alexander Wurzer, Kristina Schwamborn, Tobias Maurer, Thomas Horn, Bernhard Haller, Hans-Jürgen Wester, Matthias Eiber
Journal of Nuclear Medicine Sep 2022, 63 (9) 1334-1342; DOI: 10.2967/jnumed.121.263440
Jump to section
Related Articles
Cited By...
- No citing articles found.